**Table 2. Study population characteristics of studies included in Troponin report**

| **Author, Year** | **Group, N** | **Mean Age** | **Males, Percent** | **Dialysis status, Percent** | **Known CAD, Percent** | **CKD stage, Percent** | **Race/Ethnicity, Percent** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Abaci, 20041 | Total sample, 129 | 44 | 55 | On dialysis: 76 | NR | NR | NR |
| Abaci, 20041 | cTnT >0.1 ng/mL, 27 | 50 | 70 | NR | NR | NR | NR |
| Abaci, 20041 | cTnT 0.03-0.1 ng/mL, 27 | 46 | 59 | NR | NR | NR | NR |
| Abaci, 20041 | cTnT <0.03 ng/mL, 75 | 42 | 48 | NR | NR | NR | NR |
| Abbas, 20052 | Total sample, 222 | 67 | 65 | NR | NR | Stage 3 kidney disease, percent: 25, Stage 4 kidney disease, percent: 31, Stage 5 kidney disease, percent: 43 | NR |
| Abbas, 20052 | Stage 3, 56 | 68 | 77 | NR | NR | NR | NR |
| Abbas, 20052 | Stage 4, 70 | 71 | 70 | NR | NR | NR | NR |
| Abbas, 20052 | Stage 5, 96 | 64 | 55 | NR | NR | NR | NR |
| Acharji, 20123 | Troponin positive, 1291 | Median: 76 | 53.3 | NR | NR | NR | NR |
| Acharji, 20123 | Troponin negative, 888 | Median: 75 | 53.7 | NR | NR | NR | NR |
| Alcalai, 20074 | Nonthrombotic troponin elevation,  254 | 71.4 | 61 | NR | NR | NR | NR |
| Alcalai, 20074 | ACS, 326 | 65 | 69 | NR | NR | NR | NR |
| Alcalai, 20074 | Unknown, 35 | 72.2 | 51 | NR | NR | NR | NR |
| Alcalai, 20074 | Total sample, 615 | 68 | 65 | NR | NR | NR | NR |
| Apple, 19975 | Total sample, 16 | 46 | 44 | On dialysis: 100 | Known CAD: 56 | Stage 5 kidney disease, percent: 100 | NR |
| Apple, 19996 | Total sample, 1601 | NR | NR | NR | NR | NR | NR |
| Apple, 20027 | Total sample, 733 | 62 | 56 | On dialysis: 100 | Known CAD: 29 | Stage 5 kidney disease, percent: 100 | White: 60,  African American: 23, Hispanic: 3 |
| Apple, 20048 | Total sample, 399 | 61 | 58 | On dialysis: 100 | Known CAD: 30 | Stage 5 kidney disease, percent: 100 | White: 59, African American: 26, Hispanic: 2, Other race/ethnicity: 12 |
| Apple, 20079 | Tosoh cTnI | 57 | NR | NR | NR | NR | NR |
| Apple, 20079 | Roche cTnT, 420 | 58 | 13 | NR | NR | NR | White: 11, African American: 8, Other race/ethnicity: 4 |
| Apple, 20079 | Beckman cTnI, 421 | 58 | 14 | NR | NR | NR | White: 11, African American: 9, Other race/ethnicity: 4 |
| Apple, 20079 | Dade cTnI, 490 | 58 | 12 | NR | NR | NR | White: 10, African American: 7, Other race/ethnicity: 4 |
| Artunc, 201210 | Total sample, 239 | Median: 70 | 64 | On dialysis: 100 | Known CAD: 74 | Stage 5 kidney disease, percent: 100 | NR |
| Assa, 201311 | Total sample, 90 | Median: 67 | 57 | On dialysis: 100 | Known CAD: 40 | Stage 5 kidney disease, percent: 100 | NR |
| Aviles, 200212 | CrCl and Trop T both normal, 2605 | NR | 59 | NR | NR | NR | NR |
| Aviles, 200212 | Trop T abnormal and CrCl normal, 2695 | NR | 75 | NR | NR | NR | NR |
| Aviles, 200212 | Total sample, 7033 | NR | NR | NR | NR | NR | NR |
| Aviles, 200212 | CrCl abnormal and Trop T normal, 783 | NR | 41 | NR | NR | NR | NR |
| Aviles, 200212 | CrCl and Trop T both abnormal, 950 | NR | 51 | NR | NR | NR | NR |
| Bagheri, 200913 | CAD-, cTnT >0.05 mg/L, 10 | NR | NR | NR | NR | NR | NR |
| Bagheri, 200913 | Total sample, 138 | 65 | 52 | On dialysis: 100 | NR | NR | NR |
| Bagheri, 200913 | CAD+, cTnT <0.05 mg/L, 20 | NR | NR | NR | NR | NR | NR |
| Bagheri, 2009 13 | CAD+, cTnT >0.05 mg/L, 46 | NR | NR | NR | NR | NR | NR |
| Bagheri, 200913 | CAD-, cTnT <0.05 mg/L, 62 | NR | NR | NR | NR | NR | NR |
| Barthelemy, 201214 | CrCl ≥ to 60mL/min, 270 | 62 | NR | NR | NR | NR | NR |
| Barthelemy, 201214 | Renal failure - CrCl < 60 mL/min, 75 | 76 | NR | NR | NR | NR | NR |
| Beciani, 200315 | Group 3: >0.15ng/ml cTNI, 14 | 67 | NR | On dialysis: 100 | NR | NR | NR |
| Beciani, 200315 | Group 2: </>0.15ng/ml cTNI, 15 | 64 | NR | On dialysis: 100 | NR | NR | NR |
| Beciani, 200315 | Group 1: <0.15ng/ml cTNI, 72 | 60 | NR | On dialysis: 100 | NR | NR | NR |
| Bhagavan, 199816 | Total sample, 155 | NR | NR | NR | NR | NR | NR |
| Boulier, 200417 | Total sample, 191 | Median: 66.7 | 50.8 | On dialysis: 100 | Known CAD: 32.5 | Stage 5 kidney disease, percent: 100 | NR |
| Bozbas, 200418 | Total sample, 34 | 31.8 | 68 | On dialysis: 100 | Known CAD: 12 | Stage 5 kidney disease, percent: 294 | NR |
| Brunet, 200819 | Total sample, 105 | 65.5 | 59 | On dialysis: 100 | Known CAD: 31 | Stage 5 kidney disease, percent: 100 | NR |
| Bueti, 200620 | Total sample, 149 | Median:  63 | 49 | On dialysis: 100 | Known CAD: 43 | Stage 5 kidney disease, percent: 100 | NR |
| Chenevier-Gobeaux, 2013127 | Total sample, 367 | Mean:  57 | 65 | NR | Known CAD: 28 | Stage NR | NR |
| Chew, 200821 | Total sample, 227 | 66.26 | 54 | On dialysis: 48 | Known CAD: 63 | NR | Other race/ethnicity: 100 |
| Choy, 200322 | Total sample, 113 | Median:  63 | NR | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Choy, 200322 | cTnI>0.5, 17 | NR | NR | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Choy, 200322 | cTnT >0.1 ug/L, 48 | NR | NR | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Choy, 200322 | cTnT <0.1 ug/L, 65 | NR | NR | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Choy, 200322 | cTnI<0.5, 96 | NR | NR | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Chrysochou, 200923 | cTnT >0.03 ng/mL, 11 | 74 | 55 | NR | Known CAD: 55 | NR | NR |
| Chrysochou,  200923 | cTnT <0.03 ng/mL, 71 | 72 | 63 | NR | Known CAD: 62 | NR | NR |
| Claes, 201024 | Total sample | Median:  53 | NR | NR | Known CAD: 23.6NR | NR |  |
| Codognotto, 201025 | Total sample, 50 | 68 | 72 | On dialysis: 100 | NR | NR | NR |
| Connolly, 200826 | cTnT >0.03 ug/L, 21 | 56.5 | 76 | NR | NR | NR | NR |
| Connolly, 200826 | cTnT <0.03 ug/L, 351 | 46.7 | 64 | NR | NR | NR | NR |
| Conway, 200527 | Total sample, 75 | Median: 64 | 60 | On dialysis: 100 | Known CAD: 33 | Stage 5 kidney disease, percent: 100 | NR |
| Deegan,200128 | Total sample, 73 | Median: 64 | 58 | On dialysis: 100 | Known CAD: 25 | Stage 5 kidney disease, percent: 100 | NR |
| deFilippi,200329 | Total sample, 224 | Median: 62 | 54 | On dialysis: 100 | Known CAD: 36 | Stage 5 kidney disease, percent: 100 | White: 38, African American: 38, Hispanic: 21 |
| deFilippi,201230 | Total sample, 148 | 63.2 | 68.9 | NR | Known CAD: 16.9 | NR | White: 59.5 |
| Dierkes, 200031 | Total sample, 102 | 64 | 49 | On dialysis: 100 | Known CAD: 28 | Stage 5 kidney disease, percent: 100 | NR |
| Dierkes, 200031 | cTnT >0.04 ng/mL, 40 | NR | NR | NR | NR | NR | NR |
| Dierkes, 200031 | cTnT <0.04 ng/mL, 62 | NR | NR | NR | NR | NR | NR |
| Duman, 200532 | cTnT >0.035 ng/mL, 29 | NR | NR | NR | Known CAD: 24 | NR | NR |
| Duman, 200532 | cTnT <0.035 ng/mL, 36 | NR | NR | NR | Known CAD: 8 | NR | NR |
| Duman, 200532 | Total sample, 65 | 56 | 55 | On dialysis: 100 | Known CAD: 15 | NR | NR |
| Facila, 2006128 | creatinine >1.3, 217 | 73.8 | 71.4 | NR | Known CAD: 53 | NR | NR |
| Facila, 2006128 | Creatinine <=1.3, 812 | 67.1 | 64 | NR | Known CAD: 46 | NR | NR |
| Farkouh, 200333 | Total sample, 137 | 58 | NR | On dialysis: 100 | NR | NR | NR |
| Farkouh, 200333 | cTnI >1.0 ng/mL, 10 | 66 | 50 | On dialysis: 100 | Known CAD: 60 | NR | NR |
| Farkouh, 200333 | cTnI <1.0 ng/ml, 127 | 58 | 58 | On dialysis: 100 | Known CAD: 36 | NR | NR |
| Fehr, 200334 | Total sample, 31 | 55 | 65 | On dialysis: 100 | NR | NR | NR |
| Feringa, 200635 | Trop T >=0.10, | 70.7 | 78.3 | NR | Known CAD: 58.7 | NR | NR |
| Feringa, 200635 | Trop T 0.03-0.09, 25 | 68.6 | 76 | NR | Known CAD: 60 | NR | NR |
| Feringa, 200635 | Trop T <0.03, 487 | 66.6 | 76.6 | NR | Known CAD: 40.5 | NR | NR |
| Feringa, 200635 | Total sample, 558 | 66.6 | 76.7 | NR | Known CAD: 42.8 | NR | NR |
| Fernandez-Reyes, 200436 | Moderate risk: cTnT 0.04-0.1 ng/mL, 11 | NR | NR | NR | NR | NR | NR |
| Fernandez-Reyes, 200436 | High risk: cTnT >0.1 ng/mL, 12 | NR | NR | NR | NR | NR | NR |
| Fernandez-Reyes, 200436 | Changing group: cTnT values change during follow-up, 16 | NR | NR | NR | NR | NR | NR |
| Fernandez-Reyes, 200436 | Low risk: cTnT <0.04 ng/mL, 23 | NR | NR | NR | NR | NR | NR |
| Fernandez-Reyes, 200436 | Total sample, 58 | 69.9 | 50 | On dialysis: 100 | Known CAD: 22 | NR | NR |
| Flores, 200637 | Total sample, 467 | Median: 80 | 67 | NR | Known CAD: 19 | Stage 4 kidney disease, percent: 50 | NR |
| Flores-Solis, 201238 | Patients with other non-cardiac pathologies | 76 | 67 | NR | NR | NR | NR |
| Flores-Solis, 201238 | Patients with other cardiac pathologies, 140 | 78 | 67 | NR | NR | NR | NR |
| Flores-Solis, 201238 | Total sample, 484 | 77 | 68 | NR | NR | Stage 3 kidney disease, percent: 58, Stage 4 kidney disease, percent: 31, Stage 5 kidney disease, percent: 11 | NR |
| Flores-Solis, 201238 | Patients with ACS, 54 | 77 | 76 | NR | NR | NR | NR |
| Gaiki, 201239 | cTnI (-), 25 | NR | NR | NR | NR | NR |  |
| Gaiki, 201239 | cTnI (+), 26 | NR | NR | NR | NR | NR |  |
| Gaiki, 201239 | Total sample, 51 | 61.94 | 53 | On dialysis: 100 | Known CAD: 31 | NR | White: 18, African American: 61, Hispanic: 14, Other race/ethnicity: 8 |
| Geerse, 201240 | Total sample, 206 | 65.3 | 52 | On dialysis: 100 | Known CAD: 40 | NR | NR |
| Geerse, 201240 | >0.10 ug/L troponin, 25 | NR | NR | On dialysis: 100 | NR | NR | NR |
| Geerse, 201240 | 0.05-0.10 ug/L troponin, 28 | NR | NR | On dialysis: 100 | NR | NR | NR |
| Geerse, 201240 | <0.01 ug/L troponin, 59 | NR | NR | On dialysis: 100 | NR | NR | NR |
| Geerse, 201240 | 0.01-0.05 ug/L troponin, 94 | NR | NR | On dialysis: 100 | NR | NR | NR |
| Goicoechea, 200441 | cTnT<0.01 ng/ml w/ CKD, 108 | Median: 68 | 64 | NR | Known CAD: 19 | NR | NR |
| Goicoechea, 200441 | cTnT>0.01 w/ CKD, 20 | Median: 77 | 45 | NR | Known CAD: 35 | NR | NR |
| Goicoechea, 200441 | Control (no CKD), 48 | Median: 55.5 | 65 | On dialysis: 0 | Known CAD: 8 | NR | NR |
| Gruberg, 200242 | cTnI >0.15 ng/mL, 50 | 73 | 76 | On dialysis: 0 | Known CAD: 100 | NR | NR |
| Gruberg, 200242 | cTnI <0.15 ng/mL, 66 | 69 | 68.2 | On dialysis: 0 | Known CAD: 100 | NR | NR |
| Haaf, 201343 | Total sample, 1117 | Median: 64 | 67 | On dialysis: 0 | Known CAD: 36 | NR | NR |
| Hallen, 201144 | Total sample, 109 | 62 | 75 | On dialysis: 100 | Known CAD: 27 | NR | NR |
| Hallen, 201144 | cTnT <0.01 ug/L, 43 | NR | NR | NR | NR | NR | NR |
| Hallen, 201144 | cTnT >0.01 ug/L, 64 | NR | NR | NR | NR | NR | NR |
| Han, 200545 | Pts with no ACS, 27 | 48.1 | 63 | On dialysis: 51.9 | Known CAD: 25.9 | NR | White: 18.5, African American: 77.8, Other race/ethnicity: 3.7 |
| Han, 200545 | Pts with ACS, 34 | 61 | 50 | On dialysis: 33.3 | Known CAD: 26.5 | NR | White: 20.6, African American: 79.4, Other race/ethnicity: 0 |
| Han, 200545 | Total sample, 64 | 54.9 | 57.8 | On dialysis: 43.7 | Known CAD: 40.6 | NR | White: 18.8, African American: 79.7, Other race/ethnicity: 1.6 |
| Han, 200946 | cTnT >0.1 ug/L, 21 | 54.6 | 52 | On dialysis: 100 | NR | NR | NR |
| Han, 200946 | cTnT <0.1 ug/L, 86 | 47.8 | 44 | On dialysis: 100 | NR | NR | NR |
| Hasegawa, 201247 | Quartile 4: >33 pg/mL, | Median: 73 | NR | NR | NR | Stage 3 kidney disease, percent: 8.3, Stage 4 kidney disease, percent: 33.3, Stage 5 kidney disease, percent: 58.3 | NR |
| Hasegawa, 201247 | Quartile 3: 19-32 pg/mL, 110 | Median: 73 | 61 | On dialysis: 0 | NR | Stage 3 kidney disease, percent: 23.6, Stage 4 kidney disease, percent: 52.7, Stage 5 kidney disease, percent: 23.6 | Other race/ethnicity: 100 |
| Hasegawa, 201247 | Quartile 2: 10-18 pg/mL, 111 | Median: 68 | 67 | On dialysis: 0 | NR | Stage 3 kidney disease, percent: 35.1, Stage 4 kidney disease, percent: 49.5, Stage 5 kidney disease, percent: 15.3 | Other race/ethnicity: 100 |
| Hasegawa, 201247 | Quartile 1: <9 pg/mL, 113 | Median: 63 | 58 | On dialysis: 0 | NR | Stage 3 kidney disease, percent: 78.8, Stage 4 kidney disease, percent: 17.7, Stage 5 kidney disease, percent: 3.5 | Other race/ethnicity: 100 |
| Havekes, 2006 48 | Total sample, 847 | 59 | 60 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Heeschen, 200049 | ESRD patients, 26 | Median: 45.8 | 62 | On dialysis: 100 | Known CAD: 0 | Stage 5 kidney disease, percent: 100 | NR |
| Helleskov Madsen, 200850 | Total sample, 109 | 61.8 | 75 | On dialysis: 100 | Known CAD: 26.6 | Stage 5 kidney disease, percent: 100 | NR |
| Hickman, 200951 | Total sample, 143 | 59.67 | 63 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | White: 89.3, African American: 3.6, Other race/ethnicity: 7.1 |
| Hickson, 200852 | Total sample, 644 | 51 | 56 | On dialysis: 62 | Known CAD: 34 | NR | White: 98 |
| Hickson, 200953 | Total sample, 603 | 51 | 57 | On dialysis: 67.6 | Known CAD: 29 | NR | White: 98 |
| Hocher, 200354 | Survivors, 172 | 63.5 | 49 | On dialysis: 100 | Known CAD: 33 | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200354 | Total sample, 245 | NR | 50 | On dialysis: 100 | Known CAD: 41 | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200354 | Nonsurvivors, 73 | 70.4 | 53 | On dialysis: 100 | Known CAD: 45 | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200455 | Women, 122 | NR | NR | NR | NR | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200455 | Men, 123 | NR | NR | NR | NR | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200455 | Total sample, 245 | 63.5 | 50 | On dialysis: 100 | Known CAD: 64 | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200856 | Men, 112 | 63 | 100 | On dialysis: 100 | Known CAD: 32 | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200856 | Women, 118 | 68 | 0 | On dialysis: 100 | Known CAD: 23 | Stage 5 kidney disease, percent: 100 | NR |
| Hocher, 200856 | Total sample, 230 | 65.6 | 49 | On dialysis: 100 | Known CAD: 27 | Stage 5 kidney disease, percent: 100 | NR |
| Hojs, 200557 | Total sample, 90 | 56.2 | 61 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Holden, 201258 | Total sample, 103 | 62.9 | 69 | On dialysis: 100 | Known CAD: 47.1 | NR | NR |
| Hung, 200459 | Hypotension Prone, 29 | 61.4 | 34 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Hung, 200459 | Hypotension resistant, 41 | 58.3 | 41 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Hussein, 200460 | Total sample, 93 | 50 | 49 | On dialysis: 100 | Known CAD: 20 | Stage 5 kidney disease, percent: 100 | NR |
| Ie, 200461 | Total sample, 49 | 57 | NR | On dialysis: 100 | NR | NR | NR |
| Ikeda, 200262 | Total sample, 173 | NR | NR | NR | Known CAD: 100 | Stage 5 kidney disease, percent: 16 | Other race/ethnicity: 100 |
| Iliou, 200363 | cTnT>0.15, 18 | 63.1 | 63 | On dialysis: 100 | Known CAD: 21.7 | Stage 5 kidney disease, percent: 100 | NR |
| Iliou, 200363 | cTnT<=0.1 ng/ml, 210 | 58.5 | 58.2 | On dialysis: 100 | Known CAD: 20 | Stage 5 kidney disease, percent: 100 | NR |
| Iliou, 200363 | cTnT<=0.15, 240 | 59.6 | 57.1 | On dialysis: 100 | Known CAD: 23.1 | Stage 5 kidney disease, percent: 100 | NR |
| Iliou, 200363 | Total sample, 258 | 60.2 | 58.1 | On dialysis: 100 | Known CAD: 22.9 | Stage 5 kidney disease, percent: 100 | White: 72, African American: 15.5, Other race/ethnicity: 12.5 |
| Iliou, 200363 | cTNT>0.1 ng/ml, 48 | 67.5 | 56.2 | On dialysis: 100 | Known CAD: 35.4 | Stage 5 kidney disease, percent: 100 | NR |
| Ilva, 200864 | Total sample, 364 | 74.8 | 14 | NR | Known CAD: 13 | NR | NR |
| Ishii, 200165 | Total sample, 100 | 54 | 61 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Jensen, 201266 | hsTnT < or = 14 ng/L, 128 | 67 | 54 | NR | NR | NR | NR |
| Jensen, 201266 | hsTnT > 14 ng/L, 65 | 74 | 62 | NR | NR | NR | NR |
| Kalaji, 201267 | Total sample, 145 | Median: 45 | 55.2 | On dialysis: 100 | Known CAD: 9 | Stage 5 kidney disease, percent: 100 | NR |
| Kang, 200968 | Elevated cTnI levels, 50 | 67 | 44 | On dialysis: 100 | Known CAD: 22 | Stage 5 kidney disease, percent: 100 | NR |
| Kang, 200968 | Lower cTnI levels, 71 | 66 | 44 | On dialysis: 100 | Known CAD: 15 | Stage 5 kidney disease, percent: 100 | NR |
| Kanwar, 200669 | Total sample, 173 | 62 | 53 | On dialysis: 100 | NR | NR | White: 57 |
| Katerinis, 200870 | Elevated cTnI, 4 | 70.2 | 100 | On dialysis: 100 | Known CAD: 100 | Stage 5 kidney disease, percent: 100 | NR |
| Katerinis, 200870 | Normal cTnI, 46 | 62.2 | 61 | On dialysis: 100 | Known CAD: 35 | Stage 5 kidney disease, percent: 100 | NR |
| Kertai, 200471 | cTNT >=0.1ng/ml, 339 | NR | 79 | NR | Known CAD: 19 | NR | NR |
| Kertai, 200471 | cTNT <0.1ng/ml, 54 | NR | 83 | NR | Known CAD: 43 | NR | NR |
| Khan, 200172 | cTnI <0.03 ng/mL, 102 | 59 | 62 | On dialysis: 100 | Known CAD: 13 | Stage 5 kidney disease, percent: 100 | NR |
| Khan, 200172 | cTnI >0.03 ng/mL, 24 | 62.2 | 58 | On dialysis: 100 | Known CAD: 3 | Stage 5 kidney disease, percent: 100 | NR |
| Kontos, 200573 | Normal renal function, >60 mL/min, | 54 | NR | NR | NR | NR | NR |
| Kontos, 200573 | Severe renal failure, <30 mL/min, 329 | 65 | 47 | NR | NR | NR | NR |
| Kontos, 200573 | Total sample, 3774 | 58 | 50 | NR | NR | NR | NR |
| Kontos, 200573 | Moderate renal failure, 30-59 mL/min, 755 | 72 | 45 | NR | NR | NR | NR |
| Kontos, 200574 | CrCl >60, 2259 | 53 | 52 | NR | NR | NR | NR |
| Kontos, 200574 | CrCl <30, 233 | 64 | 45 | NR | NR | NR | NR |
| Kontos, 200574 | CrCl=30-59, 582 | 70 | 42 | NR | NR | NR | NR |
| Kontos, 200875 | Total sample, 4343 | 58 | 51 | NR | NR | NR | White: 36, African American: 64 |
| Kostrubiec, 201076 | Normal cTnI or cTnT, 122 | NR | NR | NR | NR | NR | NR |
| Kostrubiec, 201076 | Total sample, 212 | 64 | 38 | NR | Known CAD: 22 | NR | NR |
| Kostrubiec, 201076 | Elevated cTnI or cTnT, 90 | NR | NR | NR | NR | NR | NR |
| Lamb, 200777 | Total sample, 222 | 67 | 65 | On dialysis: 0 | Known CAD: 42 | Stage 3 kidney disease, percent: 25, Stage 4 kidney disease, percent: 32, Stage 5 kidney disease, percent: 43 | White: 100 |
| Lang, 200178 | Total sample, 100 | 56.6 | 62 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Le Goff, 200779 | cTnT >0.1 ug/L, 22 | NR | NR | NR | NR | NR | NR |
| Le Goff, 200779 | cTnT 0.031-0.1 ug/L, 32 | NR | NR | NR | NR | NR | NR |
| Le Goff, 200779 | cTnT <0.03 ug/L, 7 | NR | NR | NR | NR | NR | NR |
| Le Goff, 200779 | Total sample, 86 | 60 | 53 | On dialysis: 100 | Known CAD: 53 | Stage 5 kidney disease, percent: 100 | NR |
| Lowbeer, 200280 | Survivors, 11 | 52 | 36 | On dialysis: 100 | Known CAD: 0 | Stage 5 kidney disease, percent: 100 | NR |
| Lowbeer, 200280 | Non-survivors, 15 | 64 | 60 | On dialysis: 100 | Known CAD: 33 | Stage 5 kidney disease, percent: 100 | NR |
| Lowbeer, 200280 | Total sample, 26 | 58 | 50 | On dialysis: 100 | Known CAD: 19 | Stage 5 kidney disease, percent: 100 | NR |
| Lowbeer, 200381 | Total sample, 115 | 52 | 62 | On dialysis: 100 | Known CAD: 29 | Stage 5 kidney disease, percent: 100 | NR |
| Lowbeer, 200381 | HD, 49 | NR | NR | NR | NR | NR | NR |
| Lowbeer, 200381 | PD, 64 | NR | NR | NR | NR | NR | NR |
| Mallamaci, 200282 | cTnT <0.048 ug/L, | NR | NR | NR | NR | NR | NR |
| Mallamaci, 200282 | cTnT >0.098 ug/L, | NR | NR | NR | NR | NR | NR |
| Mallamaci, 200282 | cTnT 0.049-0.098 ug/L, | NR | NR | NR | NR | NR | NR |
| Mallamaci, 200282 | Total sample, 199 | 58.8 | 56 | On dialysis: 100 | NR | NR | NR |
| Martin, 199883 | Total sample, 56 | 62 | 50 | NR | NR | NR | White: 55, African American: 43, Other race/ethnicity: 2 |
| McCullough, 200284 | Quartile 1: >99.4 mL/min/72kg, 189 | 47.9 | 37.6 | On dialysis: 0 | Known CAD: 22.2 | NR | White: 16.4, African American: 78.3, Other race/ethnicity: 5.3 |
| McCullough, 200284 | Quartile 2: 99.3-72.7 mL/min/72kg, 189 | 60.9 | 48.7 | On dialysis: 0 | Known CAD: 27 | NR | White: 20.1, African American: 76.2, Other race/ethnicity: 3.7 |
| McCullough, 200284 | Quartile 4: <47.0 mL/min/72kg, 189 | 75 | 45 | On dialysis: 0 | Known CAD: 36 | NR | White: 12.7, African American: 85.7, Other race/ethnicity: 1.6 |
| McCullough, 200284 | Quartile 3: 72.8-47.0 mL/min/72kg, 190 | 70.9 | 48.9 | On dialysis: 0 | Known CAD: 35.3 | NR | White: 14.7, African American: 83.7, Other race/ethnicity: 1.6 |
| McCullough, 200284 | End stage renal disease on dialysis, 51 | 65.2 | 54.9 | On dialysis: 100 | Known CAD: 49 | NR | White: 11.8, African American: 86.3, Other race/ethnicity: 2 |
| McGill, 201085 | Total sample, 143 | NR | NR | On dialysis: 100 | NR | NR | NR |
| McMurray, 201186 | >0.028 ng/mL, 217 | 65 | 67 | NR | NR | NR | White: 64, African American: 28, Other race/ethnicity: 8 |
| McMurray, 201186 | <.028 ng/mL, 230 | 69 | 55 | NR | NR | NR | White: 62, African American: 23, Other race/ethnicity: 15 |
| McMurray, 201186 | Undetectable TnT, 548 | 68 | 30 | NR | NR | NR | White: 70, African American: 20, Other race/ethnicity: 10 |
| Melloni, 200887 | >3 x ULN cTn ratio, 20843 | Median: 70 | 59.2 | NR | NR | NR | White: 81.9 |
| Melloni, 200887 | Total sample, 31586 | Median: 70 | 58.6 | NR | NR | NR | White: 80.4 |
| Melloni, 200887 | 1-3 x ULN cTn ratio, 5214 | Median: 71 | 55.3 | NR | NR | NR | White: 77.4 |
| Melloni, 200887 | <1 x ULN cTn ratio, 5529 | Median: 66 | 59.8 | NR | NR | NR | White: 77.2 |
| Mockel, 199988 | ESRD, 20 | 51.5 | 50 | On dialysis: 100 | NR | NR | NR |
| Mockel, 199988 | Pre-ESRD, 20 | 63.5 | 60 | On dialysis: 0 | NR | NR | NR |
| Morton, 199889 | Total sample, 112 | 61.1 | 62 | On dialysis: 100 | Known CAD: 47 | Stage 5 kidney disease, percent: 100 | NR |
| Musso, 199990 | Controls, 117 | 50 | 50 | On dialysis: 0 | NR | NR | NR |
| Musso, 199990 | CRF: medical, 12 | 65 | 58 | On dialysis: 0 | NR | NR | NR |
| Musso, 199990 | CRF: transplant, 17 | 44 | 100 | On dialysis: 0 | NR | NR | NR |
| Musso, 199990 | CRF: dialysis, 20 | 51 | 50 | On dialysis: 100 | NR | NR | NR |
| Noeller, 200391 | Age >=65, 301 | NR | 57 | NR | Known CAD: 24 | NR | White: 65 |
| Noeller, 200391 | Age <65, 321 | NR | 61 | NR | Known CAD: 7 | NR | White: 51 |
| Ooi, 199992 | cTnT <0.1, 111 | Median: 61 | 53 | On dialysis: 100 | Known CAD: 28 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 199992 | cTnT >0.2, 24 | Median: 62.8 | 79 | On dialysis: 100 | Known CAD: 50 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 199992 | cTnT 0.1-0.2, 37 | Median: 64.5 | 70 | On dialysis: 100 | Known CAD: 30 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 200193 | cTnT >0.200, 26 | NR | 77 | On dialysis: 100 | Known CAD: 31 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 200193 | cTnT<0.010 ug/L, 26 | NR | 50 | On dialysis: 100 | Known CAD: 8 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 200193 | cTnT 0.100-0.199, 36 | NR | 67 | On dialysis: 100 | Known CAD: 39 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 200193 | cTnT 0.05-0.099, 62 | NR | 65 | On dialysis: 100 | Known CAD: 37 | Stage 5 kidney disease, percent: 100 | NR |
| Ooi, 200193 | cTnT 0.010-0.049, 94 | NR | 52 | On dialysis: 100 | Known CAD: 35 | Stage 5 kidney disease, percent: 100 | NR |
| Orea-Tejeda, 201094 | cTnT >0.02 ng/mL and eGFR<60, 21 | 63.19 | 47.6 | NR | NR | NR | NR |
| Peetz, 200395 | Women, 41 | 65 | 0 | On dialysis: 100 | Known CAD: 31.7 | Stage 5 kidney disease, percent: 100 | NR |
| Peetz,200395 | Men, 63 | 63 | 100 | On dialysis: 100 | Known CAD: 39.1 | Stage 5 kidney disease, percent: 100 | NR |
| Petrovic, 200996 | Total sample, 115 | 53.3 | 62 | On dialysis: 100 | NR | NR | NR |
| Porter, 199897 | Total sample, 30 | 66.1 | 40 | NR | Known CAD: 100 | NR | NR |
| Porter, 200098 | Those available for analysis and the end of the f/u period, 27 | 48.1 | 41 | On dialysis: 100 | Known CAD: 15 | Stage 5 kidney disease, percent: 100 | NR |
| Quiroga, 201399 | Total sample, 218 | 69 | 62 | NR | NR | Stage 1 kidney disease, percent: 10, Stage 2 kidney disease, percent: 17, Stage 3 kidney disease, percent: 48, Stage 4 kidney disease, percent: 23 | NR |
| Roberts, 2004100 | Negative cTnl, 79 | 59.2 | 64.6 | On dialysis: 100 | Known CAD: 25.3 | NR | NR |
| Roberts, 2004100 | Detectable cTnl, 9 | 58.6 | 55.6 | On dialysis: 100 | Known CAD: 33.3 | NR | NR |
| Roberts, 2009101 | 1-4/5 measurements cTnT >0.04 ug/L, 20 | 66.6 | 50 | NR | NR | NR | NR |
| Roberts, 2009101 | 0/5 measurements cTnT >0.04 ug/L, 28 | 56.2 | 50 | NR | NR | NR | NR |
| Roberts, 2009101 | 5/5 measurements cTnT >0.04 ug/L, 33 | 64.6 | 64 | NR | NR | NR | NR |
| Roppolo, 1999102 | Total sample, 49 | 58.5 | NR | NR | NR | NR | NR |
| Sahinarslan, 2008103 | cTnT >0.1 ug/L, 17 | NR | NR | NR | NR | NR | NR |
| Sahinarslan, 2008103 | cTnT <0.1 ug/L, 61 | NR | NR | NR | NR | NR | NR |
| Sahinarslan, 2008103 | Total sample, 78 | 53.2 | 69 | On dialysis: 100 | NR | NR | NR |
| Satyan, 2007104 | cTnT 0.056-0.106 ng/mL, 37 | 62.4 | 59 | On dialysis: 100 | Known CAD: 54 | NR | White: 8, African American: 89, Other race/ethnicity: 3 |
| Satyan, 2007104 | cTnT 0.106-0.569 ng/mL, 37 | 53.6 | 62 | On dialysis: 100 | Known CAD: 54 | NR | White: 8, African American: 92, Other race/ethnicity: 0 |
| Satyan, 2007104 | cTnT 0.01-0.022 ng/mL, 38 | 47.9 | 58 | On dialysis: 100 | Known CAD: 29 | NR | White: 5, African American: 95, Other race/ethnicity: 0 |
| Satyan, 2007104 | cTnT 0.022-0.056 ng/mL, 38 | 59.5 | 71 | On dialysis: 100 | Known CAD: 53 | NR | White: 13, African American: 84, Other race/ethnicity: 3 |
| Scheven, 2012105 | hs cTnT >0.01 ug/L, 544 | 64.2 | 78.9 | NR | NR | NR | NR |
| Scheven, 2012105 | hs cTnT <0.01 ug/L, 7577 | 49.3 | 47.7 | NR | NR | NR | NR |
| Scott, 2003106 | Total sample, 71 | 68.7 | NR | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Sharma, 2005107 | Total sample, 118 | 52 | 64 | On dialysis: 54 | Known CAD: 30 | Stage 5 kidney disease, percent: 100 | NR |
| Sharma, 2006108 | Total sample, 114 | 52 | 67 | On dialysis: 58 | Known CAD: 30 | NR | White: 45, African American: 29, Other race/ethnicity: 1 |
| Sharma, 2006108 | cTnT >0.06 ng/mL, 51 | NR | NR | NR | NR | NR | NR |
| Sharma, 2006108 | cTnT <0.06 ng/mL, 62 | NR | NR | NR | NR | NR | NR |
| Sharma, 2006109 | Total sample, 126 | 52 | 63 | On dialysis: 55 | Known CAD: 38 | Stage 5 kidney disease, percent: 100 | White: 50, African American: 25, Other race/ethnicity: 25 |
| Sharma, 2006109 | cTNT>0.1, 38 | 54 | NR | NR | Known CAD: 32 | Stage 5 kidney disease, percent: 100 | NR |
| Sharma, 2006109 | cTnT>0.04 ug/L, 52 | 54 | NR | NR | Known CAD: 22 | Stage 5 kidney disease, percent: 100 | NR |
| Sharma, 2006109 | <0.04 ug/L, 74 | 51 | NR | NR | Known CAD: 22 | Stage 5 kidney disease, percent: 100 | NR |
| Sharma, 2006109 | cTNT<0.1, 88 | 51 | NR | NR | Known CAD: 27 | Stage 5 kidney disease, percent: 100 | NR |
| Shroff, 2012110 | cTnI<0.04 ng/mL, 281 | 48.3 | 60 | On dialysis: 58 | Known CAD: 20 | NR | White: 85, African American: 6 |
| Shroff, 2012110 | cTnI>0.04 ng/mL, 95 | 52.2 | 55 | On dialysis: 65 | Known CAD: 32 | NR | White: 88, African American: 4 |
| Sommerer, 2007111 | Total sample, 134 | Median: 66 | 59.7 | On dialysis: 100 | Known CAD: 20.9 | Stage 5 kidney disease, percent: 100 | NR |
| Stolear, 1999112 | Total sample, 94 | 62.9 | 59 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Sukonthasarn, 2007113 | AMI group, 23 | 71.7 | 34.8 | NR | Known CAD: 0 | Stage 3 kidney disease, percent: 21.7, Stage 4 kidney disease, percent: 47.8, Stage 5 kidney disease, percent: 30.4 | African American: 100 |
| Sukonthasarn, 2007113 | Control group, 23 | 65.7 | 34.8 | NR | Known CAD: 8.7 | Stage 3 kidney disease, percent: 34.8, Stage 4 kidney disease, percent: 34.8, Stage 5 kidney disease, percent: 30.4 | African American: 100 |
| Svensson, 2009114 | Total sample, 206 | 67 | 65 | On dialysis: 100 | Known CAD: 100 | Stage 5 kidney disease, percent: 100 | NR |
| Trape, 2008115 | Total sample, 52 | Median: 74 | 48 | On dialysis: 100 | Known CAD: 46 | NR | NR |
| Troyanov, 2005116 | Total sample, 101 | 66 | 57 | On dialysis: 100 | Known CAD: 37 | NR | NR |
| Van Lente, 1999117 | Creatinine >20mg/L, 51 | 70.1 | 59 | On dialysis: 9 | NR | NR | NR |
| Vichairuangthum, 2006118 | cTnT >0.4 ng/mL, 14 | 63.21 | 36 | On dialysis: 100 | NR | NR | NR |
| Vichairuangthum, 2006118 | cTnT <0.08 ng/mL, 16 | 59.6 | 50 | On dialysis: 100 | NR | NR | NR |
| Vichairuangthum, 2006118 | cTnT >0.08 ng/mL, 47 | 54.6 | 47 | On dialysis: 100 | NR | NR | NR |
| Vichairuangthum, 2006118 | cTnT <0.4 ng/mL, 49 | 53.84 | 51 | On dialysis: 100 | NR | NR | NR |
| Wang, 2006119 | Total sample, 222 | 56 | 50 | On dialysis: 100 | Known CAD: 23.4 | Stage 5 kidney disease, percent: 100 | NR |
| Wang, 2007120 | cTnT <0.01 ug/L, 77 | 52.1 | 40.3 | On dialysis: 100 | Known CAD: 6.5 | NR | NR |
| Wang, 2007120 | cTnT 0.01-0.099 ug/L, 78 | 57 | 50 | On dialysis: 100 | Known CAD: 23.1 | NR | NR |
| Wang, 2007120 | cTnT >0.099 ug/L, 83 | 57.9 | 62.7 | On dialysis: 100 | Known CAD: 30.1 | NR | NR |
| Wang, 2010121 | Total sample, 230 | 56 | 50.9 | On dialysis: 100 | Known CAD: 22.6 | Stage 5 kidney disease, percent: 100 | NR |
| Wang, 2010122 | Total sample, 230 | 56 | 51 | On dialysis: 100 | Known CAD: 23 | NR | NR |
| Wang, 2010122 | cTnT 0.01-0.099 ug/L, 70 | NR | NR | NR | NR | NR | NR |
| Wang, 2010122 | cTnT >=0.1 ug/L, 79 | NR | NR | NR | NR | NR | NR |
| Wang, 2010122 | cTnT <0.01 ug/L, 81 | NR | NR | NR | NR | NR | NR |
| Wayand, 2000123 | Cardiac symptoms, 28 | 67.3 | NR | On dialysis: 100 | NR | NR | NR |
| Wayand, 2000123 | No cardiac symptoms, 31 | 51 | NR | On dialysis: 100 | NR | NR | NR |
| Wolley, 2013124 | Total sample, 238 | Median: 63 | 51 | On dialysis: 100 | Known CAD: 33 | Stage 5 kidney disease, percent: 100 | White, percent: 28, African American, percent: 0.5 |
| Wood, 2003125 | cTnT >0.1ng/mL, 25 | 59 | 68 | On dialysis: 0 | Known CAD: 36 | Stage 5 kidney disease, percent: 100 | NR |
| Wood, 2003125 | cTnT <0.1ng/mL, 71 | 50.1 | 66.2 | On dialysis: 0 | Known CAD: 19.7 | Stage 5 kidney disease, percent: 100 | NR |
| Wood, 2003125 | Total sample, 96 | 52.4 | 66.7 | On dialysis: 0 | Known CAD: 24 | Stage 5 kidney disease, percent: 100 | NR |
| Yakupoglu, 2002126 | cTnI <2.3 ng/mL, 30 | NR | NR | NR | NR | Stage 5 kidney disease, percent: 100 | NR |
| Yakupoglu, 2002126 | Total sample, 38 | 55.9 | 42 | On dialysis: 100 | NR | Stage 5 kidney disease, percent: 100 | NR |
| Yakupoglu, 2002126 | cTnI >2.3 ng/mL, 8 | NR | NR | NR | NR | Stage 5 kidney disease, percent: 100 | NR |

CAD=coronary artery disease; CrCl=creatinine clearance; CRF=chronic renal failure; cTnI=cardiac troponin I; cTnT=cardian troponin T; ECG=electrocardiography; dx=disease; ESRD=end stage renal disease; eGFR=estimated glomerular filteration rate; f/u=followup; HD=hemodialysis; hs=high sensitivity; ml/min=milliliters per minute; ng/mL=nanograms per liter; NR=not reported; NS=not specified; PD=peritoneal dialysis; pg/mL=picograms per liter; Trop=troponin; ug/L=micrograms per liter; ULN=upper limit of normal; w/=without